Metric Finance
LearnFAQ
LearnFAQ

Learn / KURA

NASDAQ: KURA

Kura Oncology (KURA) stock, explained like you're 5

Kura Oncology trades on the Nasdaq under the ticker KURA. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 943 million dollars.

Ticker
KURA
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Small cap, about 943 million dollars

Is Kura Oncology a small, medium or large cap company?

No. Kura Oncology is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 943 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Kura Oncology makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves KURA stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • KURA Stock Hits Fresh 52 Week High As CEO Buys More Shares Retail Wonders If Wilson Is Following Moderna CEO’s Playbook (Stocktwits)
  • Cantor Fitzgerald reiterates Kura Oncology stock rating at Overweight (Investing.com)
  • Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run (Yahoo Finance)
  • Kura Oncology stock has November 3 results date (ad-hoc-news.de)
  • Kura Oncology, Inc. (KURA) Discusses KO 7246 Data and Development Strategy for Menin Inhibitors in Diabetes Slideshow (NASDAQ:KURA) 2026 10 13 (Seeking Alpha)

Follow KURA in your daily brief

Each trading day at 5 PM ET we post what happened to Kura Oncology and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow KURA

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Kura Oncology stock

What does Kura Oncology do?

Kura Oncology trades on the Nasdaq under the ticker KURA. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 943 million dollars.

What is the ticker symbol for Kura Oncology?

Kura Oncology trades under the ticker KURA on the Nasdaq.

What is Kura Oncology's market cap?

Kura Oncology is a small cap stock with a market cap of about 943 million dollars.

How does Kura Oncology make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves KURA stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow KURA stock every day?

Add KURA to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow KURA daily

A free brief on Kura Oncology and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare KURA: KURA vs NVS, KURA vs AZN, KURA vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed